Ashland(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ASH Ashland

已收盘 03-24 16:00:00 EDT

50.81

+0.89

+1.78%

盘后50.81

+0.000.00%

19:27 EDT

最高51.21	最低49.30	成交量42.63万
今开49.35	昨收49.92	日振幅3.83%
总市值23.25亿	流通市值21.23亿	总股本4,576万
成交额2,163万	换手率1.02%	流通股本4,177万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ASH","market":"US","secType":"STK","nameCN":"Ashland","latestPrice":50.81,"timestamp":1774382400000,"preClose":49.92,"halted":0,"volume":426301,"hourTrading":{"tag":"盘后","latestPrice":50.81,"preClose":50.81,"latestTime":"19:27 EDT","volume":12372,"amount":628643.44,"timestamp":1774394820398,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01782852564102565,"floatShares":41773472,"shares":45762099,"eps":-15.125683,"marketStatus":"已收盘","change":0.89,"latestTime":"03-24 16:00:00 EDT","open":49.35,"high":51.21,"low":49.3,"amount":21634156.334647,"amplitude":0.038261,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-15.125683,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774425600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":49.92,"dividendRate":0.032478,"preHourTrading":{"tag":"盘前","latestPrice":50.9,"preClose":49.92,"latestTime":"09:26 EDT","volume":137,"amount":6866.629608,"timestamp":1774358805980,"change":0.98,"changeRate":0.019631,"amplitude":0.031651},"postHourTrading":{"tag":"盘后","latestPrice":50.81,"preClose":50.81,"latestTime":"19:27 EDT","volume":12372,"amount":628643.44,"timestamp":1774394820398,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.511522,"impliedVol":0.2526,"impliedVolPercentile":0.0319},"requestUrl":"/m/hq/s/ASH","defaultTab":"news","newsList":[{"id":"1136606639","title":"SELLAS生命科学公布2025财年业绩及战略进展 GPS三期临床试验迎关键节点","url":"https://stock-news.laohu8.com/highlight/detail?id=1136606639","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136606639?lang=zh_cn&edition=full","pubTime":"2026-03-20 04:09","pubTimestamp":1773950977,"startTime":"0","endTime":"0","summary":"在急性髓系白血病领域取得重大临床进展的SELLAS生命科学集团近日公布了截至2025年12月31日的全年财务业绩，并同步更新了公司最新发展动态。这家专注于创新癌症疗法开发的临床阶段生物制药公司宣布，其主导产品Galinpepimut-S的三期REGAL试验即将迎来最终分析，同时SLS009在早期治疗领域的拓展也取得突破性进展。我们正积极推进GPS三期REGAL试验的最终分析，该试验针对接受二线挽救治疗后达到完全缓解的AML患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","SLS","ASH","BK4139","BK4109"],"gpt_icon":0},{"id":"1111647859","title":"亚什兰集团更新业绩展望：卡弗特城项目延期及恶劣天气造成约1100万美元临时影响，均局限于第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1111647859","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111647859?lang=zh_cn&edition=full","pubTime":"2026-02-03 06:06","pubTimestamp":1770069974,"startTime":"0","endTime":"0","summary":"亚什兰集团（Ashland Inc.）最新发布的业绩展望显示，公司预计将面临约1100万美元的临时性财务影响。这一影响主要源于卡弗特城（Calvert City）项目启动延迟以及近期恶劣天气造成的运营中断。\n值得注意的是，这些不利因素全部集中在今年第二季度，预计不会对公司长期财务表现产生持续性冲击。管理层表示，相关挑战已得到有效控制，运营正逐步回归正轨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","ASH","BK4109"],"gpt_icon":0},{"id":"1140467717","title":"亚什兰集团预计全年将遵循典型季节性节奏 商业活动与运营效率提升推动下半年业绩走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1140467717","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140467717?lang=zh_cn&edition=full","pubTime":"2026-02-03 06:06","pubTimestamp":1770069973,"startTime":"0","endTime":"0","summary":"亚什兰集团预测，随着商业活动持续活跃及运营效率不断提升，公司全年业绩将呈现典型的季节性波动模式，下半年表现有望显著优于上半年。\n这一预期基于公司核心业务的周期性特征，以及近期在成本控制和流程优化方面取得的实质性进展。管理层指出，当前市场需求环境保持健康，特别是特种化学品板块的订单量呈现稳步增长态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","ASH","BK4109"],"gpt_icon":0},{"id":"2593720654","title":"2025 ASH | 强生公布 CD19/CD20 双靶点 CAR-T 1b 期最新临床进展与生物标志物分析！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593720654","media":"医麦客","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593720654?lang=zh_cn&edition=full","pubTime":"2025-12-24 07:20","pubTimestamp":1766532031,"startTime":"0","endTime":"0","summary":"2025 年 12 月 24 日医麦客新闻 eMedClub News本月 9 日，强生在第 65 届美国血液学会年会上以口头报告形式，更新了其双靶点 CAR-T 疗法 Prizlo-cel的 1b 期临床试验数据及生物标志物关联分析。目前也仅有约 40% 的患者通过现有的单抗原靶向 CD19 CAR-T 细胞疗法获得长期缓解。ORR 达 91%，CR 率 75% 该数据显著优于传统 CD19 CAR-T 历史数据。Grade 3 中位数略高，但 Grade 1 和 Grade 2 中同样有高峰值浓度样本，并未显示 ICANS 严重程度与 CAR-T 细胞扩增有显著关联。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224072631a470912f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224072631a470912f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0345769128.USD","BK4504","LU0234572021.USD","LU0466842654.USD","SG9999002224.SGD","LU0787776722.HKD","LU2463526074.USD","IE0034235303.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU1032955483.USD","LU2750360641.GBP","LU1244550577.SGD","LU2468319806.SGD","IE00BZ1G4Q59.USD","JNJ","IE00B19Z3581.USD","LU0114720955.EUR","LU1059921491.USD","LU0795875086.SGD","IE00B42XCP33.USD","CAR","IE00B1BXHZ80.USD","LU0203347892.USD","LU1162221912.USD","BK4022","LU1496350502.SGD","LU1778281490.HKD","LU2750360997.AUD","LU0234570918.USD","LU2430703095.HKD","LU2112291526.USD","IE00BGHQF631.EUR","LU0070217475.USD","LU1280957306.USD","LU1196500208.SGD","BK4592","LU1732799900.SGD","LU2505996509.AUD","LU1057294990.SGD","IE00BFXG1179.USD","LU2129689431.USD","ASH","IE00BFTCPJ56.SGD","LU1023059063.AUD","BK4534","IE00B7SZLL34.SGD","LU2505996681.GBP","IE00B4R5TH58.HKD","BK4559"],"gpt_icon":0},{"id":"2590583770","title":"迪哲医药ASH大会发布高瑞哲®与Birelentinib淋巴瘤治疗最新积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583770","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590583770?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:56","pubTimestamp":1765360604,"startTime":"0","endTime":"0","summary":"中访网数据 迪哲(江苏)医药股份有限公司在第67届美国临床血液学会年会上，公布了其两款全球首创新药在淋巴瘤治疗领域的最新临床研究进展。另一方面，其非共价LYN/BTK双靶点抑制剂Birelentinib在B细胞淋巴瘤领域取得新进展。公司同时披露了Birelentinib联合疗法治疗弥漫性大B细胞淋巴瘤的后续研究计划。这些数据进一步验证了迪哲医药两款核心产品的临床价值，为其在淋巴瘤治疗领域的商业化前景提供了支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31856740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2463526074.USD","688192","ASH","BK4109","BK0239"],"gpt_icon":0},{"id":"2590373303","title":"股海导航_2025年12月10日_沪深股市公告与交易提示","url":"https://stock-news.laohu8.com/highlight/detail?id=2590373303","media":"股市直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590373303?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:27","pubTimestamp":1765326420,"startTime":"0","endTime":"0","summary":"　　博瑞传播：拟6649.02万元收购每经科技51%股权。　　天有为：拟100万欧元购买克莱默汽车系统有限公司100%股权。　　3连板升兴股份：目前正在筹划向特定对象发行股票事项。　　富乐德：拟转让参股公司海古德410.07万股 预计产生1.8亿元投资收益。　　英派斯：控股股东拟6000万元至1.2亿元增持公司股份。　　金融街：和谐健康近日增持703.84万股公司股份。　　中国人寿：截至2025年11月30日，公司总保费超7000亿元","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-12-10/doc-inhahhpm2300213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ASH","BK4109","LU2463526074.USD"],"gpt_icon":0},{"id":"2590390894","title":"港股异动 | 维立志博-B(09887)涨超3% LBL-034突破性数据于2025 ASH年会口头报告发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2590390894","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590390894?lang=zh_cn&edition=full","pubTime":"2025-12-09 14:37","pubTimestamp":1765262240,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B涨超3%，截至发稿，涨2.39%，报53.6港元，成交额5125.77万港元。消息面上，维立志博-B发布公告，于2025年12月6日至9日，第67届ASH年会在美国佛罗里达州奥兰多召开。公司自主研发用于治疗复发性╱难治性多发性骨髓瘤的GPRC5D/CD3双特异性抗体LBL-034在大会首日第一个进行口头报告。2024年10月LBL-034获得FDA的孤儿药认定，用于治疗多发性骨髓瘤。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","09887","ASH","HK0000500386.USD","LU2463526074.USD","BK4109"],"gpt_icon":0},{"id":"2590316824","title":"【直击2025 ASH】亚盛医药耐立克®二线治疗CML-CP临床研究数据更新，更前线治疗潜力明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316824","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590316824?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:34","pubTimestamp":1765244040,"startTime":"0","endTime":"0","summary":"此次公布是对该研究在2024 ASH年会口头报告结果的持续更新，展现了更长时间的随访疗效与安全性特征。此次更新的研究结果进一步提示耐立克有望为二线CML-CP患者带来一种安全有效的治疗选择，尤其对那些一线使用二代BCR-ABL1酪氨酸激酶抑制剂治疗失败的患者。此次数据的更新，进一步体现了耐立克为更广泛的CML患者群体提供安全有效治疗选择的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842159_ZH42159_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","AAPG","BK4109","ASH","BK4585","BK4588","BK4016","LU2463526074.USD","LU1261432733.SGD","06855","CP","BK1161","BK4139"],"gpt_icon":0},{"id":"2589272354","title":"Syndax公布AML联合疗法强劲数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589272354","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589272354?lang=zh_cn&edition=full","pubTime":"2025-12-08 23:42","pubTimestamp":1765208520,"startTime":"0","endTime":"0","summary":"美股周一早盘，临床阶段的生物制药公司Syndax（SNDX）股价下跌3.2%。该公司在2025年美国血液学会（ASH）年会上展示了revumenib联合疗法的最新数据，在新诊断和移植后急性髓系白血病患者队列中显示出高缓解率和高微小残留病阴性率。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-08/doc-inhachkx2122015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4109","ASH","LU2463526074.USD","BK4139","SNDX"],"gpt_icon":0},{"id":"2590451393","title":"吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590451393?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:58","pubTimestamp":1765166299,"startTime":"0","endTime":"0","summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B3T34201.USD","BK4566","BK4109","LU0109394709.USD","LU0882574055.USD","IE00B66KJ199.SGD","LU0889565916.HKD","LU1674673691.USD","KOL","BK4187","IE00B19Z3581.USD","BK4550","IE00B7SZL793.SGD","PFS","LU1839511570.USD","LU0320765992.SGD","CRS","GILD","BK4578","IE00B7SZLL34.SGD","IE00B19Z4B17.USD","BK4588","LU1674673428.USD","OS","BK4139","IE00BZ1G4Q59.USD","SG9999015978.USD","SG9999015986.USD","CR","IE0002270589.USD","LU1778281490.HKD","SG9999015945.SGD","BK4585","IE00B19Z3B42.SGD","ASH","LU0823416689.USD","LU1571399168.USD","BK4195","IE00BKVL7J92.USD","LU0234570918.USD","BK4097","BK4532","LU0289739699.SGD","LU1066051498.USD","BK4568","LU1430594728.SGD","ORR","SG9999015952.SGD","LU1585245621.USD"],"gpt_icon":0},{"id":"2589384810","title":"ASH 2025口头报告：信达生物公布其三特异性抗体 -IBI3003治疗复发或难治性多发性骨髓瘤患者的首次人体试验的初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589384810","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589384810?lang=zh_cn&edition=full","pubTime":"2025-12-08 09:04","pubTimestamp":1765155840,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年12月8日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，在2025年美国血液学会年会上以口头报告形式首次公布其自主开发的抗GPRC5D/BCMA/CD3三特异性抗体IBI3003用于复发或难治性多发性骨髓瘤患者的首次人体试验的初步数据。IBI3003的剂量优化研究正在积极推进中。我们也更为期待IBI3003持续治疗下长期随访的生存数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4840966_ZH40966_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2097828714.EUR","IVBIY","LU2097828631.EUR","LU0502904849.HKD","LU2488822045.USD","LU2242644610.SGD","LU1969619763.USD","LU2097828474.EUR","LU2463526074.USD","LU2097828805.USD","BK1589","BK4109","ASH","01801","HK0000165453.HKD","BK1583","LU0455707207.USD","BK1161","BK4139","LU2328871848.SGD","LU2097828557.USD"],"gpt_icon":0},{"id":"2589874964","title":"金斯瑞生物科技(01548)：传奇宣布于2025年ASH年会上公布报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2589874964","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589874964?lang=zh_cn&edition=full","pubTime":"2025-12-07 19:04","pubTimestamp":1765105452,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 发布公告，传奇生物科技股份有限公司于2025年12月6日发布新闻稿宣布于2025年美国血液学会年会上通过一项口头报告公布了CARVYKTI在复发或难治性多发性骨髓瘤患者中开展的CARTITUDE-1和CARTITUDE-4研究长期随访的临床及转化研究数据，以及III期研究CARTITUDE-4的最新结果，还通过六项壁报展示了CARVYKTI在不同亚组中的缓解持久性数据及真实世界研究结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","HK0000306701.USD","BK4109","HK0000320223.HKD","01548","ASH","LU2463526074.USD","HK0000306685.HKD","BK1583","HK0000320264.USD"],"gpt_icon":0},{"id":"2589871029","title":"维立志博-B(09887)：LBL-034临床数据于第67届ASH年会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2589871029","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589871029?lang=zh_cn&edition=full","pubTime":"2025-12-07 18:28","pubTimestamp":1765103333,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2025年12月6日至9日，第67届ASH年会在美国佛罗里达州奥兰多召开。公司自主研发用于治疗复发性╱难治性多发性骨髓瘤的GPRC5D/CD3双特异性抗体LBL-034在大会首日第一个进行口头报告。LBL-034的主要临床亮点包括：LBL-034剂量递增至1,200μg/kg，未观察到任何剂量限制性毒性，未达到最大耐受剂量。与生活质量密切相关不良事件均为1至2级，多数不良事件发生于第一周期，在后续治疗中的发生率显著降低，不影响治疗连续性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000252160.HKD","BK4109","HK0000500386.USD","ASH","BK1161","LU2463526074.USD","09887"],"gpt_icon":1},{"id":"2589187505","title":"周末，利好来了！两部门，重磅发布！","url":"https://stock-news.laohu8.com/highlight/detail?id=2589187505","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589187505?lang=zh_cn&edition=full","pubTime":"2025-12-07 14:15","pubTimestamp":1765088100,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　创新药板块，迎来利好消息！　　今日，2025年国家医保药品目录及首版商保创新药目录正式发布。　　国家医保局、人力资源社会保障部表示，要积极推进商保创新药目录药品配备使用，积极推动商保创新药目录纳入商业健康保险保障范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-07/doc-infzxzyp2912318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4109","06978","ASH","BK1574","BK1161","SINA","LU2463526074.USD"],"gpt_icon":0},{"id":"2586729952","title":"和黄医药(00013)将于2025年欧洲肿瘤内科学会 (ESMO) 亚洲年会和 2025年美国血液学会 (ASH) 年会公布临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2586729952","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586729952?lang=zh_cn&edition=full","pubTime":"2025-11-27 08:05","pubTimestamp":1764201920,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，和黄医药自主研发的化合物的数项研究的最新及更新后的数据将于2025年12月5日至7日在新加坡召开的欧洲肿瘤内科学会亚洲年会，以及 2025年12月6日至9日在美国奥兰多召开的美国血液学会年会上公布。抗CD47单克隆抗体HMPL-A83用于治疗晚期实体瘤的首个人体临床试验结果，以及呋喹替尼 联合信迪利单抗用于二线治疗局部晚期或转移性肾细胞癌的FRUSICA-2注册研究中II期部分的结果将于 2025年ESMO亚洲年会公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","00013","BK1587","BK4007","BK4531","BK4588","BK4585","ASH","BK1588","BK4109","HCM","BK1191"],"gpt_icon":0},{"id":"2584323984","title":"国产三抗新药首次公布临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2584323984","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584323984?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:28","pubTimestamp":1763378888,"startTime":"0","endTime":"0","summary":"2025 年美国血液学会年会将于当地时间 12 月 6 日到 12 月 9 日在美国佛罗里达州奥兰多市召开，目前常规摘要已经公布。齐鲁制药将在本次会议上首次公布下一代GPRC5D×BCMA×CD3三抗 QLS4131在复发或难治性多发性骨髓瘤患者中首次人体试验的初步研究结果。这是一项评价QLS4131 在 RRMM 患者中的安全性、耐受性、药代动力学、免疫原性以及初步有效性的 I 期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117223327a4a7ede6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117223327a4a7ede6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4452.SGD","BK4533","IE00BFXG1179.USD","IE0034235303.USD","LU2129689605.HKD","BK4187","LU0320765646.SGD","LU1674673691.USD","LU0203345920.USD","KG","CRS","LU0203347892.USD","LU1914381329.SGD","PR","IE00BFTCPJ56.SGD","IE00B19Z4B17.USD","BK4007","IE00B7SZL793.SGD","IE00BGHQF631.EUR","MTD","IE00BVYPNV92.GBP","LU1074936037.SGD","SG9999001440.SGD","LU0889566641.SGD","LU0882574055.USD","IE00BSNM7G36.USD","BK4019","BK4532","BK4585","IE00BJJMRZ35.SGD","BK4581","BK4567","ASH","JNJ","IE00B7SZLL34.SGD","LU1732800096.USD","LU0963586101.USD","LU2592432038.USD","LU0792757196.USD","BK4121","LU0070217475.USD","LU1066053197.SGD","LU0122379950.USD","LU2129689431.USD","TRAE","LU2129689514.USD","BK4534","LU1244550577.SGD","LU2413666699.HKD","LU0098860793.USD"],"gpt_icon":0},{"id":"2581171560","title":"港股异动 | 维立志博-B(09887)涨超3% 5项血液肿瘤领域研究成果于2025 ASH年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2581171560","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581171560?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:20","pubTimestamp":1762312846,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B(09887)涨超3%，截至发稿，涨3.49%，报57.9港元，成交额2020.56万港元。消息面上，11月4日，维立志博-B发布公告，内容有关5篇研究摘要入选美国血液学会以于其第67届年会上展示。公司欣然提供有关其在研创新药 LBL-034及LBL-076的进一步详情，该等药物的多份研究摘要已被第67届ASH年会收录。其中，1项LBL-034临床研究获选在大会首日作第一个口头报告，展示LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","BK1161","ASH","09887","BK4109"],"gpt_icon":0},{"id":"2580785963","title":"迪哲医药(688192.SH)：高瑞哲®和Birelentinib多项研究入选第67届美国临床血液学会(ASH)大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2580785963","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580785963?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:12","pubTimestamp":1762247572,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司将于12月6日至9日在第67届美国临床血液学会(American Society of Hematology，ASH)大会上，公布淋巴瘤治疗领域两大核心产品高瑞哲®(通用名：戈利昔替尼胶囊)和birelentinib(DZD8586)多项最新研究成果。本次大会，公司共有15篇摘要入选，充分展现了公司在血液肿瘤治疗领域的丰富管线组合以及研发潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239","BK4109","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2580220496","title":"亚盛医药-B(06855)耐立克®、利生妥®、APG-5918的多项临床进展将在2025年美国血液学会年会(ASH)展示，其中一项获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2580220496","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580220496?lang=zh_cn&edition=full","pubTime":"2025-11-04 08:21","pubTimestamp":1762215703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司3个品种有多项临床和临床前进展入选第67届美国血液学会年会展示及报告，其中一项获口头报告。此外，公司原创1类新药利沙托克拉共 有 2项临床进展获选第67届ASH年会，其中一项获口头报告。这是该品种的临床进展连续第4年入选 ASH年会。第67届ASH年会将于当地时间2025年12月6 日至12月9日间在美国佛罗里达州奥兰多市以线下结合线上的形式举行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["APG","BK4129","LU2125909759.SGD","AAPG","BK1161","LU1923622291.USD","ASH","06855","BK1574","BK4139","LU2125909916.SGD","LU2463526074.USD","BK4109"],"gpt_icon":0},{"id":"2580622162","title":"维立志博-B(09887)：1项LBL-034临床研究获选在第67届ASH年会首日作第一个口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2580622162","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580622162?lang=zh_cn&edition=full","pubTime":"2025-11-04 06:37","pubTimestamp":1762209451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，内容有关5篇研究摘要入选美国血液学会以于其第67届年会上展示。公司欣然提供有关其在研创新药 LBL-034及LBL-076的进一步详情，该等药物的多份研究摘要已被第67届ASH年会收录。其中，1项LBL-034临床研究获选在大会首日作第一个口头报告，展示LBL-034对复发╱难治性多发性骨髓瘤患者的最新疗效及安全性数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","ASH","LU2463526074.USD","09887","BK4109"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ashland.com","stockEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":-0.2296},{"period":"3month","weight":-0.1549},{"period":"6month","weight":0.0126},{"period":"1year","weight":-0.1157},{"period":"ytd","weight":-0.1491}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ashland Inc.是特拉华州的一家公司。亚什兰是为广泛的消费和工业市场客户提供特种材料的全球领导者，包括建筑涂料、建筑、能源、食品和饮料、营养保健品、个人护理和制药。亚什兰为100多个国家的客户提供服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.543478,"avgChangeRate":0.003875},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001708},{"month":3,"riseRate":0.608696,"avgChangeRate":0.03353},{"month":4,"riseRate":0.565217,"avgChangeRate":0.045566},{"month":5,"riseRate":0.608696,"avgChangeRate":0.019604},{"month":6,"riseRate":0.478261,"avgChangeRate":-0.00607},{"month":7,"riseRate":0.391304,"avgChangeRate":-0.006667},{"month":8,"riseRate":0.543478,"avgChangeRate":0.002878},{"month":9,"riseRate":0.391304,"avgChangeRate":-0.017418},{"month":10,"riseRate":0.478261,"avgChangeRate":-0.005907},{"month":11,"riseRate":0.608696,"avgChangeRate":0.010224},{"month":12,"riseRate":0.543478,"avgChangeRate":0.015582}],"exchange":"NYSE","name":"Ashland","nameEN":"Ashland"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ashland(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ashland(ASH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ashland,ASH,Ashland股票,Ashland股票老虎,Ashland股票老虎国际,Ashland行情,Ashland股票行情,Ashland股价,Ashland股市,Ashland股票价格,Ashland股票交易,Ashland股票购买,Ashland股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ashland(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ashland(ASH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}